Methotrexate vs. Mycophenolate for Uveitis: What the Head-to-Head Trial Found
Methotrexate vs. Mycophenolate for Uveitis at a Glance
Your eye doctor may have named two drugs to calm long-term swelling inside the eye: methotrexate and mycophenolate mofetil. A large trial put them head to head. The good news is that they work about equally well for most people. In that trial, named FAST, 64 of 96 people on methotrexate had their eye inflammation controlled at six months, or about 67 of every 100. On mycophenolate, it was 56 of 98, or about 57 of every 100. The gap between them was small, and not big enough to count as a real difference. 1 So neither drug wins for everyone. The best choice depends on your type of uveitis, your other health, side effects, and cost.
Uveitis means inflammation inside the eye. When it is not caused by an infection and it affects the middle or back of the eye (intermediate, posterior, or panuveitis), it is usually treated first with corticosteroids and then with a steroid-sparing medicine so the inflammation can be controlled without the harms of long-term steroids. 2 Left untreated, this kind of inflammation can scar the retina and threaten vision, which is why controlling it matters even when your eye feels only mildly irritated.
Use this page to prepare for a conversation, not to pick a drug on your own. Both medicines are prescription immune-modulating treatments that need a specialist's supervision and regular blood tests. Bring your full medication list and your plans about pregnancy to the visit, because those details often decide which drug is safer for you.
What Each Medicine Is and How It Is Used
Methotrexate is an antimetabolite, a medicine that dials down an overactive immune response. It is one of the antimetabolites commonly used as an initial steroid-sparing treatment for uveitis. 1 In the FAST trial it was taken by mouth once a week, at a dose of 25 milligrams. 1 Taking it only weekly is a practical advantage for some people, though the once-a-week schedule must be followed exactly, since taking methotrexate daily by mistake is dangerous.
Mycophenolate mofetil is also an antimetabolite, and it is another first-line steroid-sparing choice for the same kinds of uveitis. In the FAST trial it was taken by mouth twice a day, adding up to 3 grams daily. 1 Both methotrexate and mycophenolate are used to control noninfectious uveitis while lowering the steroid dose, and the FAST trial was run specifically to see which one does that job better. 3
Corticosteroids such as prednisone calm eye inflammation quickly, but long-term, high-dose steroid use risks serious side effects including osteoporosis, diabetes, and weight gain, along with eye problems such as glaucoma and cataract, which is the reason doctors add a steroid-sparing medicine for anyone who needs treatment for months. 4 Methotrexate and mycophenolate let many people taper their steroids to a low, safer dose while keeping the inflammation quiet.
How the Two Compare: What the FAST Trial Found
| Feature | Methotrexate | Mycophenolate mofetil |
|---|---|---|
| Inflammation controlled at 6 months | 64 of 96 (about 67 of 100) | 56 of 98 (about 57 of 100) |
| Posterior uveitis / panuveitis | 58 of 78 (about 74 of 100) | 42 of 76 (about 55 of 100) |
| How it is taken | Once weekly by mouth | Twice daily by mouth |
These figures come from the FAST trial, which randomly assigned 216 patients across India, the United States, Australia, Saudi Arabia, and Mexico. 1
The main comparison was close enough that neither drug clearly beat the other for the whole group. But among people with posterior uveitis or panuveitis, the more severe forms, methotrexate controlled inflammation in 58 of 78 people (about 74 of every 100) compared with 42 of 76 (about 55 of every 100) on mycophenolate, and that difference was statistically significant. 1 The trial's overall conclusion was that methotrexate is as good as or better than mycophenolate for treating this kind of uveitis. 4
Because the two drugs worked so similarly overall, practical factors carry real weight. In the United States, mycophenolate cost more than five times as much as methotrexate at the time of the trial. 4 Dosing schedule matters too: a weekly pill suits some people better, while others tolerate a twice-daily medicine more easily. Your specialist weighs these alongside your other conditions.
There is no single right answer, and this page cannot choose for you. In general, methotrexate is often tried first given its lower cost and its edge in more severe disease, while mycophenolate may be preferred when methotrexate is not tolerated or is unsafe because of another condition. Your eye specialist makes this call with you after reviewing your health history.
Risks, Side Effects, and Long-Term Outlook
Both medicines can cause nausea, tiredness, and changes in blood tests, and both can occasionally affect the liver or blood counts. In the FAST trial, mildly elevated liver enzymes were the most common non-serious lab finding, seen in about 13 of every 100 people on methotrexate and about 7 of every 100 on mycophenolate. 1 These changes are usually caught early on routine blood tests and improve when the dose is adjusted, which is exactly why the monitoring below is not optional.
Both methotrexate and mycophenolate require periodic blood tests while you take them. The methotrexate label directs blood counts, liver tests, and renal function to be checked at baseline, periodically during treatment, and as clinically indicated. 5 For mycophenolate, the label advises a complete blood count weekly for the first month, twice monthly for the second and third months, and monthly for the rest of the first year. 6 Keeping these appointments is the single most important thing you can do to use these drugs safely; the tests let your team lower a dose or switch medicines long before a problem becomes serious.
This is one area where there is no ambiguity. Methotrexate can cause miscarriage and serious birth defects and must not be used during pregnancy for uveitis; both women and men should use reliable contraception during treatment and for a period after stopping. 5 Mycophenolate mofetil likewise raises the risk of first-trimester pregnancy loss and birth defects, so a pregnancy test and reliable contraception are required before and during treatment. 6 If you may want to become pregnant, tell your specialist early: pregnancies are planned around these medicines by switching to a safer option well ahead of time, and many people go on to have healthy pregnancies with that planning.
Not everyone responds to the first medicine tried, and that is a known, manageable step rather than a dead end. If inflammation is not controlled on one antimetabolite, specialists commonly switch to the other, combine treatments, or move to a biologic medicine. The realistic outlook for noninfectious uveitis today is that most people can reach good, steroid-sparing control through one of these pathways, though the exact result varies from person to person.
When to Call Your Doctor
While taking either medicine, call your eye doctor the same day if you notice a sudden drop in vision, new eye pain, a new shower of floaters, flashes of light, or a curtain or shadow across your sight, because these can signal a flare or a retinal problem that should be checked promptly rather than waited out. Also call promptly for signs of infection such as fever, a persistent sore throat, or mouth ulcers, or for yellowing of the skin or eyes, since these medicines lower the immune response and can affect the liver.
Uveitis that needs steroid-sparing medicine is managed by an eye specialist, often a uveitis or retina specialist, sometimes together with a rheumatologist. Expect scheduled eye exams and the regular blood tests described above. Do not stop either drug on your own, even if your eye feels fine, because stopping suddenly can let inflammation return.
Reach out between visits if side effects are affecting your daily life, if you are having trouble keeping to the dosing schedule, if you are planning a pregnancy, or if you are starting any new medicine or supplement, since some interact with these drugs. A quick call often prevents a missed dose or an avoidable side effect.
Common Questions About These Two Uveitis Medicines
Not clearly, for most people. In the FAST trial the two drugs controlled inflammation at similar rates overall, and the difference was not statistically significant. Methotrexate did have a real advantage in the more severe forms, posterior uveitis and panuveitis, and it costs less in the United States. For milder or intermediate uveitis, either can be a reasonable first choice. Your specialist decides based on your uveitis type, other health conditions, and how you tolerate each medicine.
Both antimetabolites work gradually, not overnight, and it commonly takes several weeks to a few months to see the full steroid-sparing effect. That is why doctors usually keep you on a corticosteroid at first and taper it slowly as the antimetabolite takes hold. If your inflammation is not improving after an adequate trial, your specialist may adjust the dose, switch to the other drug, or add another treatment rather than simply waiting longer.
Often yes, at least at the start. These drugs are called steroid-sparing because their goal is to let you lower the steroid dose, not always to eliminate it immediately. Many people taper to a low prednisone dose, or off steroids entirely, once the antimetabolite is controlling the inflammation. The plan is individual, so follow your specialist's tapering schedule rather than stopping steroids on your own.
Talk to your doctor before drinking any alcohol, especially on methotrexate. Both alcohol and these medicines can affect the liver, and combining them raises that risk. Many specialists advise avoiding alcohol or keeping it to a strict minimum while on methotrexate. Your regular blood tests check liver function, and being honest with your team about alcohol helps them keep the medicine safe for you.
More Questions Before You Decide
These drugs lower the immune response, so infections can be more frequent or take longer to clear, which is why you should report fevers and persistent infections promptly. Regarding cancer, large studies of immune-modulating therapy for eye inflammation have been broadly reassuring for antimetabolites in people without an existing increased risk. Your specialist weighs your personal risk factors, keeps vaccinations up to date where appropriate, and monitors you over time.
Tell your specialist as early as possible, ideally before trying to conceive. Both methotrexate and mycophenolate can cause serious harm to a pregnancy and are not used while pregnant for uveitis. With planning, your team switches you to a pregnancy-compatible approach ahead of time, and both partners follow contraception guidance until then. This is a manageable, well-trodden path, but only if the conversation happens before, not after, a pregnancy begins.
Coverage varies by payer and plan, so ask your specialist's office and your insurer directly. Cost can genuinely influence the choice: methotrexate is typically far less expensive in the United States, which is one reason it is often tried first. If cost or coverage is a barrier for either drug, tell your care team, since patient-assistance programs and alternative options may be available.
- Which type of uveitis do I have, and does that make one of these medicines a better first choice for me?
- How often will I need blood tests, and what are you watching for?
- What side effects should prompt me to call you the same day?
- What is the plan for tapering my steroids as this medicine takes effect?
- What should I do about contraception or pregnancy planning while on this drug?
- If this medicine does not control my inflammation, what is the next step?
- Ophthalmology (Rathinam et al.), PubMed Central full text (2019). A Randomized Clinical Trial Comparing Methotrexate and Mycophenolate Mofetil for Noninfectious Uveitis (FAST).
- EyeWiki (American Academy of Ophthalmology) (2024). Treatment of Uveitis.
- American Academy of Ophthalmology, EyeNet Magazine (2019). Methotrexate Versus Mycophenolate Mofetil for Uveitis.
- National Eye Institute (NIH) (2019). Two commonly used uveitis drugs perform similarly in NIH-funded clinical trial.
- DailyMed (U.S. National Library of Medicine) (2023). Methotrexate tablet - Prescribing Information.
- DailyMed (U.S. National Library of Medicine) (2023). Mycophenolate Mofetil capsule - Prescribing Information and Medication Guide.